ANVS May 2024 7.500 call
| Previous close | 0.9900 |
| Open | 0.3500 |
| Bid | 0.4000 |
| Ask | 1.3000 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2500 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.25k |
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
ZacksKodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
GlobeNewswireAnnovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improveme
